Literature DB >> 20663531

Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.

Maxim Totrov1, Xunqing Jiang, Xiang-Peng Kong, Sandra Cohen, Chavdar Krachmarov, Aidy Salomon, Constance Williams, Michael S Seaman, Ruben Abagyan, Timothy Cardozo, Miroslaw K Gorny, Shixia Wang, Shan Lu, Abraham Pinter, Susan Zolla-Pazner.   

Abstract

V3 loop is a major neutralizing determinant of the HIV-1 gp120. Using 3D structures of cholera toxin B subunit (CTB), complete V3 in the gp120 context, and V3 bound to a monoclonal antibody (mAb), we designed two V3-scaffold immunogen constructs (V3-CTB). The full-length V3-CTB presenting the complete V3 in a structural context mimicking gp120 was recognized by the large majority of our panel of 24 mAbs. The short V3-CTB presenting a V3 fragment in the conformation observed in the complex with the 447-52D Fab, exhibited high-affinity binding to this mAb. The immunogens were evaluated in rabbits using DNA-prime/protein-boost protocol. Boosting with the full-length V3-CTB induced high anti-V3 titers in sera that potently neutralize multiple HIV virus strains. The short V3-CTB was ineffective. The results suggest that very narrow antigenic profile of an immunogen is associated with poor Ab response. An immunogen with broader antigenic activity elicits robust Ab response. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20663531      PMCID: PMC2942080          DOI: 10.1016/j.virol.2010.06.027

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  85 in total

1.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Authors:  A Trkola; T Dragic; J Arthos; J M Binley; W C Olson; G P Allaway; C Cheng-Mayer; J Robinson; P J Maddon; J P Moore
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

2.  Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

Authors:  T Muster; R Guinea; A Trkola; M Purtscher; A Klima; F Steindl; P Palese; H Katinger
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

3.  Immunological characterization of a rotavirus-neutralizing epitope fused to the cholera toxin B subunit.

Authors:  R A González; J Sánchez; J Holmgren; S López; C F Arias
Journal:  Gene       Date:  1993-11-15       Impact factor: 3.688

4.  Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins.

Authors:  R Abagyan; M Totrov
Journal:  J Mol Biol       Date:  1994-01-21       Impact factor: 5.469

5.  Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.

Authors:  L Eckhart; W Raffelsberger; B Ferko; A Klima; M Purtscher; H Katinger; F Rüker
Journal:  J Gen Virol       Date:  1996-09       Impact factor: 3.891

6.  An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein.

Authors:  C Bergmann; S A Stohlmann; M McMillan
Journal:  Eur J Immunol       Date:  1993-11       Impact factor: 5.532

7.  Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli.

Authors:  M Bckström; J Holmgren; F Schödel; M Lebens
Journal:  Gene       Date:  1995-11-20       Impact factor: 3.688

8.  Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.

Authors:  S C Kayman; Z Wu; K Revesz; H Chen; R Kopelman; A Pinter
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

9.  Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit.

Authors:  M Bäckström; M Lebens; F Schödel; J Holmgren
Journal:  Gene       Date:  1994-11-18       Impact factor: 3.688

10.  The three-dimensional crystal structure of cholera toxin.

Authors:  R G Zhang; D L Scott; M L Westbrook; S Nance; B D Spangler; G G Shipley; E M Westbrook
Journal:  J Mol Biol       Date:  1995-08-25       Impact factor: 5.469

View more
  29 in total

1.  Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.

Authors:  Susan Zolla-Pazner; Rebecca Powell; Sara Yahyaei; Constance Williams; Xunqing Jiang; Wei Li; Shan Lu; Shixia Wang; Chitra Upadhyay; Catarina E Hioe; Max Totrov; Xiangpeng Kong
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

2.  Can HIV p24 be a suitable scaffold for presenting Env antigens?

Authors:  Luigi Buonaguro; Maria Tagliamonte; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2011-09-07

3.  Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.

Authors:  Timothy Cardozo; Shixia Wang; Xunqing Jiang; Xiang-Peng Kong; Catarina Hioe; Chavdar Krachmarov
Journal:  Vaccine       Date:  2014-07-18       Impact factor: 3.641

4.  Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.

Authors:  Rajnish Kumar; Michael Tuen; Jianping Liu; Arthur Nàdas; Ruimin Pan; Xiangpeng Kong; Catarina E Hioe
Journal:  Vaccine       Date:  2013-09-16       Impact factor: 3.641

5.  Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.

Authors:  Xunqing Jiang; Max Totrov; Wei Li; Jared M Sampson; Constance Williams; Hong Lu; Xueling Wu; Shan Lu; Shixia Wang; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

6.  An HIV Vaccine Targeting the V2 Region of the HIV Envelope Induces a Highly Durable Polyfunctional Fc-Mediated Antibody Response in Rhesus Macaques.

Authors:  Rebecca L Powell; Svenja Weiss; Alisa Fox; Xiaomei Liu; Vincenza Itri; Xunqing Jiang; Christina C Luo; David A Spencer; Shilpi Pandey; Tracy Cheever; Deborah H Fuller; Maxim Totrov; Ann J Hessell; Nancy L Haigwood; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

7.  Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.

Authors:  Zakiya M Qualls; Alok Choudhary; William Honnen; Raja Prattipati; James E Robinson; Abraham Pinter
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

8.  Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer.

Authors:  Liuzhe Li; Xiao-Hong Wang; Sagarika Banerjee; Barbara Volsky; Constance Williams; M Anthony Moody; Susan Zolla-Pazner; Miroslaw K Gorny
Journal:  Hum Antibodies       Date:  2012

9.  Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses.

Authors:  Ann J Hessell; Rebecca Powell; Xunqing Jiang; Christina Luo; Svenja Weiss; Vincent Dussupt; Vincenza Itri; Alisa Fox; Mariya B Shapiro; Shilpi Pandey; Tracy Cheever; Deborah H Fuller; Byung Park; Shelly J Krebs; Maxim Totrov; Nancy L Haigwood; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  Cell Rep       Date:  2019-07-23       Impact factor: 9.423

10.  A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.

Authors:  Liuzhe Li; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Olivia Steczko; Michael S Seaman; Kalpana Luthra; Phillipe Nyambi; Arthur Nadas; Véronique Giudicelli; Marie-Paule Lefranc; Susan Zolla-Pazner; Miroslaw K Gorny
Journal:  Mol Immunol       Date:  2015-05-18       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.